Home » Stocks » CRIS

Curis, Inc. (CRIS)

Stock Price: $1.44 USD 0.07 (5.11%)
Updated November 27, 1:00 PM EST - Market closed
After-hours: $1.42 -0.02 (-1.39%) Nov 27, 4:45 PM

Stock Price Chart

Key Info

Market Cap 84.70M
Revenue (ttm) 11.10M
Net Income (ttm) -31.00M
Shares Out 58.82M
EPS (ttm) -0.77
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $1.44
Previous Close $1.37
Change ($) 0.07
Change (%) 5.11%
Day's Open 1.38
Day's Range 1.37 - 1.44
Day's Volume 592,013
52-Week Range 0.62 - 3.59

More Stats

Market Cap 84.70M
Enterprise Value 69.07M
Earnings Date (est) Jan 1, 1970
Ex-Dividend Date n/a
Shares Outstanding 58.82M
Float n/a
EPS (basic) -0.82
EPS (diluted) -0.77
FCF / Share -0.48
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 430,882
Short Ratio 1.27
Short % of Float n/a
Beta 2.20
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 7.63
PB Ratio n/a
Revenue 11.10M
Operating Income -25.96M
Net Income -31.00M
Free Cash Flow -26.28M
Net Cash 15.63M
Net Cash / Share 0.27
Gross Margin -115.35%
Operating Margin -233.89%
Profit Margin -279.30%
FCF Margin -236.80%
ROA -36.89%
ROE n/a
ROIC -489.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$4.75*
(229.86% upside)
Low
4.00
Current: $1.44
High
5.00
Target: 4.75
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue10.0010.439.907.537.889.8415.0016.9714.7616.00
Revenue Growth-4.07%5.35%31.5%-4.46%-19.96%-34.39%-11.61%14.97%-7.73%-
Gross Profit9.509.879.407.137.479.5014.8016.8014.7616.00
Operating Income-24.36-29.33-49.76-58.04-56.48-15.86-9.42-18.62-7.20-5.64
Net Income-32.14-32.58-53.32-60.41-58.98-18.73-12.32-16.42-9.86-4.44
Shares Outstanding33.1833.1229.8326.5624.6717.1916.4715.8115.2714.99
Earnings Per Share-0.97-0.98-1.79-2.25-2.40-1.10-0.75-1.05-0.65-0.30
Operating Cash Flow-26.21-30.07-48.36-35.81-29.89-16.81-9.54-15.19-4.56-1.63
Capital Expenditures-0.04-0.09-0.19-0.33-0.02-0.09-0.15-0.10-0.18-0.18
Free Cash Flow-26.25-30.15-48.54-36.14-29.92-16.90-9.69-15.30-4.75-1.80
Cash & Equivalents20.7024.4260.2344.4982.1949.7658.1955.5537.7240.60
Total Debt0.1735.4841.5619.8624.1728.3030.5629.84--
Net Cash / Debt20.53-11.0618.6824.6358.0321.4727.6425.7137.7240.60
Assets35.1137.3773.8057.7594.9762.6180.5969.7748.1850.65
Liabilities69.0241.8649.8128.4930.4632.8335.4235.508.305.13
Book Value-33.91-4.5023.9929.2764.5129.7845.1734.2739.8845.52
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Curis, Inc.
Country United States
Employees 28
CEO James E. Dentzer

Stock Information

Ticker Symbol CRIS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CRIS
IPO Date August 1, 2000

Description

Curis, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation; and Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors. The company's products in pipeline include CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and DarwinHealth, Inc. to characterize biomarkers and tumor subtype alignments to identify therapeutic opportunities. The company was founded in 2000 and is headquartered in Lexington, Massachusetts.